[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcc_buMha2BWlv6J-1Td7VYbEmvQQb8yz92mpyfu5c3k":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"University of Campinas, Brazil",[4],165,false,9,17,17743,2,94,[14,17,19,22,25,28,31,33],{"name":15,"count":16},"Diabetes Mellitus, Type 2",10,{"name":18,"count":8},"Obesity",{"name":20,"count":21},"Dental Caries",8,{"name":23,"count":24},"Insulin Resistance",7,{"name":26,"count":27},"Hypertension",6,{"name":29,"count":30},"Coronary Artery Disease",4,{"name":32,"count":30},"Periodontal Diseases",{"name":34,"count":35},"Endophthalmitis",3,[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06601101","Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus","2025-10-01","Insulin",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06711185","Effect of DAPAglifozin on MYOcardial Remodeling of Breast CANCER Patients Treated with Anthracycline Based Chemotherapy","2026-01-30","Dapagliflozin 10 mg",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,93,117,142,160,186,215,239,266,284,310,338,356,382,400,426,449,473,499,525,552,570,595,625,643,661,679,703,733,751,776,802,827,853,876,904,922,949,975,993,1022,1040,1058,1076,1110,1143,1168,1192,1216,1234,1260,1286,1304,1335,1359,1386,1404,1429,1447,1471,1489,1514,1536,1562,1580,1598,1623,1645,1671,1689,1716,1754,1789,1821,1844,1862,1887,1905,1923,1941,1959,1984,2007,2032,2056,2074,2104,2130,2148,2174,2192,2210,2233,2256],{"intervention":46,"totalTrials":11,"cells":56},{"EARLY_PHASE1":57,"PHASE1":60,"PHASE2":62,"PHASE3":64,"PHASE4":76,"NA":91},{"trials":58,"activeCount":59},[],0,{"trials":61,"activeCount":59},[],{"trials":63,"activeCount":59},[],{"trials":65,"activeCount":75,"soonestReadout":45},[66],{"nctId":43,"briefTitle":44,"status":67,"phases":68,"primaryCompletion":45,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[51],"2026-08-30","2024-01-30",80,[73],"Breast Cancer",[46],1,{"trials":77,"activeCount":59},[78],{"nctId":79,"briefTitle":80,"status":81,"phases":82,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":89},"NCT02919345","Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery","COMPLETED",[52],"2018-12","2019-03","2017-01",98,[15,29,88],"Carotid Artery Diseases",[46,90],"Glibenclamide 5 mg",{"trials":92,"activeCount":59},[],{"intervention":41,"totalTrials":75,"cells":94},{"EARLY_PHASE1":95,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":113,"NA":115},{"trials":96,"activeCount":59},[],{"trials":98,"activeCount":59},[],{"trials":100,"activeCount":59},[],{"trials":102,"activeCount":75,"soonestReadout":40},[103],{"nctId":38,"briefTitle":39,"status":67,"phases":104,"primaryCompletion":40,"completion":40,"start":105,"enrollment":106,"conditions":107,"interventions":112},[51],"2024-08-01",36,[108,109,110,111],"Keratoconus","Cornea Disease","Eye Diseases","Wound Heal",[41],{"trials":114,"activeCount":59},[],{"trials":116,"activeCount":59},[],{"intervention":118,"totalTrials":75,"cells":119},"30 mcg EE and 150 LNG oral contraceptive",{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":126,"PHASE4":128,"NA":140},{"trials":121,"activeCount":59},[],{"trials":123,"activeCount":59},[],{"trials":125,"activeCount":59},[],{"trials":127,"activeCount":59},[],{"trials":129,"activeCount":59},[130],{"nctId":131,"briefTitle":132,"status":81,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":136,"conditions":137,"interventions":139},"NCT01388582","The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth",[52],"2011-08","2011-04",40,[138],"Underweight",[118],{"trials":141,"activeCount":59},[],{"intervention":90,"totalTrials":75,"cells":143},{"EARLY_PHASE1":144,"PHASE1":146,"PHASE2":148,"PHASE3":150,"PHASE4":152,"NA":158},{"trials":145,"activeCount":59},[],{"trials":147,"activeCount":59},[],{"trials":149,"activeCount":59},[],{"trials":151,"activeCount":59},[],{"trials":153,"activeCount":59},[154],{"nctId":79,"briefTitle":80,"status":81,"phases":155,"primaryCompletion":83,"completion":84,"start":85,"enrollment":86,"conditions":156,"interventions":157},[52],[15,29,88],[46,90],{"trials":159,"activeCount":59},[],{"intervention":161,"totalTrials":75,"cells":162},"Dapagliflozin",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":169,"PHASE4":171,"NA":184},{"trials":164,"activeCount":59},[],{"trials":166,"activeCount":59},[],{"trials":168,"activeCount":59},[],{"trials":170,"activeCount":59},[],{"trials":172,"activeCount":59},[173],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"completion":179,"start":180,"enrollment":71,"conditions":181,"interventions":183},"NCT05685394","DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease","UNKNOWN",[52],"2024-11-01","2024-12-01","2023-01-24",[182],"End-stage Kidney Disease",[161],{"trials":185,"activeCount":59},[],{"intervention":187,"totalTrials":75,"cells":188},"BCG",{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":193,"PHASE3":195,"PHASE4":197,"NA":213},{"trials":190,"activeCount":59},[],{"trials":192,"activeCount":59},[],{"trials":194,"activeCount":59},[],{"trials":196,"activeCount":59},[],{"trials":198,"activeCount":59},[199],{"nctId":200,"briefTitle":201,"status":81,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":212},"NCT04369794","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",[52],"2022-06-04","2023-08-02","2020-10-01",400,[208,209,187,210,211],"COVID-19","Therapeutic Vaccine","SARS-CoV 2","Transmission",[187],{"trials":214,"activeCount":59},[],{"intervention":216,"totalTrials":75,"cells":217},"Triclosan",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":237},{"trials":219,"activeCount":59},[],{"trials":221,"activeCount":59},[],{"trials":223,"activeCount":59},[],{"trials":225,"activeCount":59},[],{"trials":227,"activeCount":59},[228],{"nctId":229,"briefTitle":230,"status":81,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":136,"conditions":234,"interventions":236},"NCT03642353","Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.",[52],"2016-12-20","2016-01-30",[235],"Generalized Aggressive Periodontitis",[216],{"trials":238,"activeCount":59},[],{"intervention":240,"totalTrials":75,"cells":241},"In-office and at home Colgate sensitive pro-relief - CSPR",{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":264},{"trials":243,"activeCount":59},[],{"trials":245,"activeCount":59},[],{"trials":247,"activeCount":59},[],{"trials":249,"activeCount":59},[],{"trials":251,"activeCount":59},[252],{"nctId":253,"briefTitle":254,"status":81,"phases":255,"primaryCompletion":256,"completion":257,"start":258,"enrollment":259,"conditions":260,"interventions":262},"NCT02461030","Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Periodontal Treatment",[52],"2014-11","2014-12","2014-08",60,[261,32],"Dentin Sensitivity",[240,263],"In-office Villevie® prophy paste + Colgate Toothpaste",{"trials":265,"activeCount":59},[],{"intervention":263,"totalTrials":75,"cells":267},{"EARLY_PHASE1":268,"PHASE1":270,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":282},{"trials":269,"activeCount":59},[],{"trials":271,"activeCount":59},[],{"trials":273,"activeCount":59},[],{"trials":275,"activeCount":59},[],{"trials":277,"activeCount":59},[278],{"nctId":253,"briefTitle":254,"status":81,"phases":279,"primaryCompletion":256,"completion":257,"start":258,"enrollment":259,"conditions":280,"interventions":281},[52],[261,32],[240,263],{"trials":283,"activeCount":59},[],{"intervention":285,"totalTrials":75,"cells":286},"Pioglitazone 45 mg",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":295,"NA":308},{"trials":288,"activeCount":59},[],{"trials":290,"activeCount":59},[],{"trials":292,"activeCount":59},[],{"trials":294,"activeCount":59},[],{"trials":296,"activeCount":59},[297],{"nctId":298,"briefTitle":299,"status":176,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT05775380","The Role of Pioglitazone in Vascular Transcriptional Remodeling",[52],"2024-06-28","2024-12-22","2023-06-15",20,[306],"Myocardial Reperfusion Injury",[285],{"trials":309,"activeCount":59},[],{"intervention":311,"totalTrials":75,"cells":312},"Botulinum Toxin Type A",{"EARLY_PHASE1":313,"PHASE1":315,"PHASE2":317,"PHASE3":319,"PHASE4":321,"NA":336},{"trials":314,"activeCount":59},[],{"trials":316,"activeCount":59},[],{"trials":318,"activeCount":59},[],{"trials":320,"activeCount":59},[],{"trials":322,"activeCount":59},[323],{"nctId":324,"briefTitle":325,"status":81,"phases":326,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":334},"NCT01460355","Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone",[52],"2007-06","2008-06","2006-09",23,[332,333],"Esotropia","Exotropia",[311,335],"saline solution",{"trials":337,"activeCount":59},[],{"intervention":335,"totalTrials":75,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":354},{"trials":341,"activeCount":59},[],{"trials":343,"activeCount":59},[],{"trials":345,"activeCount":59},[],{"trials":347,"activeCount":59},[],{"trials":349,"activeCount":59},[350],{"nctId":324,"briefTitle":325,"status":81,"phases":351,"primaryCompletion":327,"completion":328,"start":329,"enrollment":330,"conditions":352,"interventions":353},[52],[332,333],[311,335],{"trials":355,"activeCount":59},[],{"intervention":357,"totalTrials":75,"cells":358},"Levonorgestrel",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":380},{"trials":360,"activeCount":59},[],{"trials":362,"activeCount":59},[],{"trials":364,"activeCount":59},[],{"trials":366,"activeCount":59},[],{"trials":368,"activeCount":59},[369],{"nctId":370,"briefTitle":371,"status":81,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":378},"NCT02480647","Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis",[52],"2017-08","2016-05",100,[377],"Endometriosis",[357,379],"Etonogestrel",{"trials":381,"activeCount":59},[],{"intervention":379,"totalTrials":75,"cells":383},{"EARLY_PHASE1":384,"PHASE1":386,"PHASE2":388,"PHASE3":390,"PHASE4":392,"NA":398},{"trials":385,"activeCount":59},[],{"trials":387,"activeCount":59},[],{"trials":389,"activeCount":59},[],{"trials":391,"activeCount":59},[],{"trials":393,"activeCount":59},[394],{"nctId":370,"briefTitle":371,"status":81,"phases":395,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":396,"interventions":397},[52],[377],[357,379],{"trials":399,"activeCount":59},[],{"intervention":401,"totalTrials":75,"cells":402},"Niacin",{"EARLY_PHASE1":403,"PHASE1":405,"PHASE2":407,"PHASE3":409,"PHASE4":411,"NA":424},{"trials":404,"activeCount":59},[],{"trials":406,"activeCount":59},[],{"trials":408,"activeCount":59},[],{"trials":410,"activeCount":59},[],{"trials":412,"activeCount":59},[413],{"nctId":414,"briefTitle":415,"status":81,"phases":416,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT01942291","Short-term Effect of Extended-release Niacin on Endothelial Function.",[52],"2012-12","2013-06","2012-03",18,[422],"Hypoalphalipoproteinemia",[401],{"trials":425,"activeCount":59},[],{"intervention":427,"totalTrials":75,"cells":428},"Infliximab",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":433,"PHASE3":435,"PHASE4":437,"NA":447},{"trials":430,"activeCount":59},[],{"trials":432,"activeCount":59},[],{"trials":434,"activeCount":59},[],{"trials":436,"activeCount":59},[],{"trials":438,"activeCount":59},[439],{"nctId":440,"briefTitle":441,"status":81,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":16,"conditions":445,"interventions":446},"NCT02743390","Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension",[52],"2017-07","2015-03",[26],[427],{"trials":448,"activeCount":59},[],{"intervention":450,"totalTrials":75,"cells":451},"N-acetylcysteine",{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":471},{"trials":453,"activeCount":59},[],{"trials":455,"activeCount":59},[],{"trials":457,"activeCount":59},[],{"trials":459,"activeCount":59},[],{"trials":461,"activeCount":59},[462],{"nctId":463,"briefTitle":464,"status":176,"phases":465,"primaryCompletion":466,"start":467,"enrollment":259,"conditions":468,"interventions":470},"NCT02241876","THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS",[52],"2016-12","2014-10",[469],"Head and Neck Neoplasms",[450],{"trials":472,"activeCount":59},[],{"intervention":474,"totalTrials":75,"cells":475},"Hydrogen peroxide",{"EARLY_PHASE1":476,"PHASE1":478,"PHASE2":480,"PHASE3":482,"PHASE4":484,"NA":497},{"trials":477,"activeCount":59},[],{"trials":479,"activeCount":59},[],{"trials":481,"activeCount":59},[],{"trials":483,"activeCount":59},[],{"trials":485,"activeCount":59},[486],{"nctId":487,"briefTitle":488,"status":81,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":30,"conditions":493,"interventions":496},"NCT03019224","Effects of Desensitizing Dentifrices on the Reduction of Pain Sensitivity Caused by In-office Dental Whitening",[52],"2016-04","2016-08","2016-01",[494,495],"Tooth Whitening","Sensitivity",[474],{"trials":498,"activeCount":59},[],{"intervention":500,"totalTrials":75,"cells":501},"Ulipristal acetate",{"EARLY_PHASE1":502,"PHASE1":504,"PHASE2":506,"PHASE3":508,"PHASE4":510,"NA":523},{"trials":503,"activeCount":59},[],{"trials":505,"activeCount":59},[],{"trials":507,"activeCount":59},[],{"trials":509,"activeCount":59},[],{"trials":511,"activeCount":59},[512],{"nctId":513,"briefTitle":514,"status":176,"phases":515,"primaryCompletion":516,"completion":516,"start":517,"enrollment":518,"conditions":519,"interventions":522},"NCT03186586","Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena",[52],"2018-07-30","2017-07-01",32,[520,521],"Heavy Menstrual Bleeding","Abnormal Bleeding",[500],{"trials":524,"activeCount":59},[],{"intervention":526,"totalTrials":75,"cells":527},"Hydroxypropylmethylcellulose",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":550},{"trials":529,"activeCount":59},[],{"trials":531,"activeCount":59},[],{"trials":533,"activeCount":59},[],{"trials":535,"activeCount":59},[],{"trials":537,"activeCount":59},[538],{"nctId":539,"briefTitle":540,"status":81,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT01280110","The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients",[52],"2011-12","2012-01","2011-03",44,[547],"Dry Eye Syndromes",[526,549],"Carboxymethylcellulose",{"trials":551,"activeCount":59},[],{"intervention":549,"totalTrials":75,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":59},[],{"trials":557,"activeCount":59},[],{"trials":559,"activeCount":59},[],{"trials":561,"activeCount":59},[],{"trials":563,"activeCount":59},[564],{"nctId":539,"briefTitle":540,"status":81,"phases":565,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":566,"interventions":567},[52],[547],[526,549],{"trials":569,"activeCount":59},[],{"intervention":571,"totalTrials":75,"cells":572},"Doxicicline",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":593},{"trials":574,"activeCount":59},[],{"trials":576,"activeCount":59},[],{"trials":578,"activeCount":59},[],{"trials":580,"activeCount":59},[],{"trials":582,"activeCount":59},[583],{"nctId":584,"briefTitle":585,"status":81,"phases":586,"primaryCompletion":257,"completion":587,"start":588,"enrollment":589,"conditions":590,"interventions":592},"NCT02487186","Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy.",[52],"2015-06","2010-03",30,[591],"Periodontal Disease",[571],{"trials":594,"activeCount":59},[],{"intervention":596,"totalTrials":75,"cells":597},"travoprost and timolol maleate fixed combination",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":623},{"trials":599,"activeCount":59},[],{"trials":601,"activeCount":59},[],{"trials":603,"activeCount":59},[],{"trials":605,"activeCount":59},[],{"trials":607,"activeCount":59},[608],{"nctId":609,"briefTitle":610,"status":81,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":619},"NCT01978015","Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG",[52],"2012-07","2013-01","2011-10",69,[617,618],"Uveitis, Anterior","Cystoid Macular Edema",[596,620,621,622],"latanoprost and maleate timolol fixed combination","bimatoprost and timolol maleate fixed combination","dextran and hypromellose",{"trials":624,"activeCount":59},[],{"intervention":620,"totalTrials":75,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":635,"NA":641},{"trials":628,"activeCount":59},[],{"trials":630,"activeCount":59},[],{"trials":632,"activeCount":59},[],{"trials":634,"activeCount":59},[],{"trials":636,"activeCount":59},[637],{"nctId":609,"briefTitle":610,"status":81,"phases":638,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":639,"interventions":640},[52],[617,618],[596,620,621,622],{"trials":642,"activeCount":59},[],{"intervention":621,"totalTrials":75,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":651,"PHASE4":653,"NA":659},{"trials":646,"activeCount":59},[],{"trials":648,"activeCount":59},[],{"trials":650,"activeCount":59},[],{"trials":652,"activeCount":59},[],{"trials":654,"activeCount":59},[655],{"nctId":609,"briefTitle":610,"status":81,"phases":656,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":657,"interventions":658},[52],[617,618],[596,620,621,622],{"trials":660,"activeCount":59},[],{"intervention":622,"totalTrials":75,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":677},{"trials":664,"activeCount":59},[],{"trials":666,"activeCount":59},[],{"trials":668,"activeCount":59},[],{"trials":670,"activeCount":59},[],{"trials":672,"activeCount":59},[673],{"nctId":609,"briefTitle":610,"status":81,"phases":674,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":675,"interventions":676},[52],[617,618],[596,620,621,622],{"trials":678,"activeCount":59},[],{"intervention":680,"totalTrials":75,"cells":681},"Ketorolac Tromethamine",{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":701},{"trials":683,"activeCount":59},[],{"trials":685,"activeCount":59},[],{"trials":687,"activeCount":59},[],{"trials":689,"activeCount":59},[],{"trials":691,"activeCount":59},[692],{"nctId":693,"briefTitle":694,"status":81,"phases":695,"primaryCompletion":417,"completion":696,"start":697,"enrollment":71,"conditions":698,"interventions":700},"NCT01542190","Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery",[52],"2013-08","2011-02",[699],"Cystoid Macular Edema Following Cataract Surgery, Bilateral",[680],{"trials":702,"activeCount":59},[],{"intervention":704,"totalTrials":75,"cells":705},"Dapagliflozin 10mg",{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":714,"NA":731},{"trials":707,"activeCount":59},[],{"trials":709,"activeCount":59},[],{"trials":711,"activeCount":59},[],{"trials":713,"activeCount":59},[],{"trials":715,"activeCount":59},[716],{"nctId":717,"briefTitle":718,"status":81,"phases":719,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":724,"interventions":729},"NCT03089333","Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects",[52],"2017-10","2017-12","2016-07",16,[26,15,725,18,726,727,728],"Blood Pressure","Cardiac Hypertrophy","Microalbuminuria","Vascular Stiffness",[704,730],"Glibenclamide 5Mg",{"trials":732,"activeCount":59},[],{"intervention":730,"totalTrials":75,"cells":734},{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":741,"PHASE4":743,"NA":749},{"trials":736,"activeCount":59},[],{"trials":738,"activeCount":59},[],{"trials":740,"activeCount":59},[],{"trials":742,"activeCount":59},[],{"trials":744,"activeCount":59},[745],{"nctId":717,"briefTitle":718,"status":81,"phases":746,"primaryCompletion":720,"completion":721,"start":722,"enrollment":723,"conditions":747,"interventions":748},[52],[26,15,725,18,726,727,728],[704,730],{"trials":750,"activeCount":59},[],{"intervention":752,"totalTrials":75,"cells":753},"Enamel Matrix Proteins",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":774},{"trials":755,"activeCount":59},[],{"trials":757,"activeCount":59},[],{"trials":759,"activeCount":59},[],{"trials":761,"activeCount":59},[],{"trials":763,"activeCount":59},[764],{"nctId":765,"briefTitle":766,"status":81,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":773},"NCT03025204","Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis",[52],"2018-04","2016-02",45,[772],"Aggressive Periodontitis",[752],{"trials":775,"activeCount":59},[],{"intervention":777,"totalTrials":75,"cells":778},"amoxicillin",{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":785,"PHASE4":787,"NA":800},{"trials":780,"activeCount":59},[],{"trials":782,"activeCount":59},[],{"trials":784,"activeCount":59},[],{"trials":786,"activeCount":59},[],{"trials":788,"activeCount":59},[789],{"nctId":790,"briefTitle":791,"status":81,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":796,"conditions":797,"interventions":799},"NCT01933698","Bioequivalence of Two Commercial Amoxicillin Suspensions",[52],"2005-05","2005-07","2005-02",25,[798],"Bioequivalence of Amoxicillin",[777],{"trials":801,"activeCount":59},[],{"intervention":803,"totalTrials":75,"cells":804},"Atorvastatin",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":825},{"trials":806,"activeCount":59},[],{"trials":808,"activeCount":59},[],{"trials":810,"activeCount":59},[],{"trials":812,"activeCount":59},[],{"trials":814,"activeCount":59},[815],{"nctId":816,"briefTitle":817,"status":81,"phases":818,"primaryCompletion":819,"completion":820,"start":821,"enrollment":375,"conditions":822,"interventions":824},"NCT00610545","Atorvastatin in Perioperative Vascular Surgery - Pilot Study",[52],"2008-09","2008-12","2007-07",[823],"Vascular Surgery",[803,803],{"trials":826,"activeCount":59},[],{"intervention":828,"totalTrials":75,"cells":829},"Dapagliflozin 10Mg Tab",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":851},{"trials":831,"activeCount":59},[],{"trials":833,"activeCount":59},[],{"trials":835,"activeCount":59},[],{"trials":837,"activeCount":59},[],{"trials":839,"activeCount":59},[840],{"nctId":841,"briefTitle":842,"status":81,"phases":843,"primaryCompletion":844,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":850},"NCT05343078","Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients",[52],"2022-09-01","2022-10-01","2022-04-25",5,[849],"End-stage Renal Disease",[828],{"trials":852,"activeCount":59},[],{"intervention":854,"totalTrials":75,"cells":855},"EMD",{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":874},{"trials":857,"activeCount":59},[],{"trials":859,"activeCount":59},[],{"trials":861,"activeCount":59},[],{"trials":863,"activeCount":59},[],{"trials":865,"activeCount":59},[866],{"nctId":867,"briefTitle":868,"status":81,"phases":869,"primaryCompletion":257,"completion":587,"start":870,"enrollment":871,"conditions":872,"interventions":873},"NCT02474498","EMD and\u002For Bone Substitute for the Treatment of Class II Furcations",[52],"2013-03",41,[591],[854],{"trials":875,"activeCount":59},[],{"intervention":877,"totalTrials":75,"cells":878},"4% articaine with 1:100,000 epinephrine",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":902},{"trials":880,"activeCount":59},[],{"trials":882,"activeCount":59},[],{"trials":884,"activeCount":59},[],{"trials":886,"activeCount":59},[],{"trials":888,"activeCount":59},[889],{"nctId":890,"briefTitle":891,"status":81,"phases":892,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":897,"interventions":900},"NCT01912755","Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits",[52],"2010-11","2011-01","2010-02",50,[898,899],"Irreversible Pulpitis","Pain",[877,901],"2% lidocaine with 1:100,000 epinephrine",{"trials":903,"activeCount":59},[],{"intervention":901,"totalTrials":75,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":920},{"trials":907,"activeCount":59},[],{"trials":909,"activeCount":59},[],{"trials":911,"activeCount":59},[],{"trials":913,"activeCount":59},[],{"trials":915,"activeCount":59},[916],{"nctId":890,"briefTitle":891,"status":81,"phases":917,"primaryCompletion":893,"completion":894,"start":895,"enrollment":896,"conditions":918,"interventions":919},[52],[898,899],[877,901],{"trials":921,"activeCount":59},[],{"intervention":923,"totalTrials":75,"cells":924},"Evolocumab 140 MG\u002FML",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":947},{"trials":926,"activeCount":59},[],{"trials":928,"activeCount":59},[],{"trials":930,"activeCount":59},[],{"trials":932,"activeCount":59},[],{"trials":934,"activeCount":59},[935],{"nctId":936,"briefTitle":937,"status":81,"phases":938,"primaryCompletion":939,"completion":940,"start":941,"enrollment":942,"conditions":943,"interventions":946},"NCT03932721","EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial",[52],"2021-06-30","2021-10-30","2018-10-01",110,[944,15,945],"Dyslipidemia Associated With Type II Diabetes Mellitus","Hypertension Arterial",[923],{"trials":948,"activeCount":59},[],{"intervention":950,"totalTrials":75,"cells":951},"amoxicillin and metronidazole",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":973},{"trials":953,"activeCount":59},[],{"trials":955,"activeCount":59},[],{"trials":957,"activeCount":59},[],{"trials":959,"activeCount":59},[],{"trials":961,"activeCount":59},[962],{"nctId":963,"briefTitle":964,"status":81,"phases":965,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":971},"NCT03933501","Amoxicillin and Metronidazole in Association With Non-surgical Therapy in Aggressive Periodontitis Treatment",[52],"2008-12-01","2018-12-01","2006-01-01",48,[235],[950,972],"Placebos",{"trials":974,"activeCount":59},[],{"intervention":972,"totalTrials":75,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":991},{"trials":978,"activeCount":59},[],{"trials":980,"activeCount":59},[],{"trials":982,"activeCount":59},[],{"trials":984,"activeCount":59},[],{"trials":986,"activeCount":59},[987],{"nctId":963,"briefTitle":964,"status":81,"phases":988,"primaryCompletion":966,"completion":967,"start":968,"enrollment":969,"conditions":989,"interventions":990},[52],[235],[950,972],{"trials":992,"activeCount":59},[],{"intervention":994,"totalTrials":75,"cells":995},"Amoxicillin 500mg",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1020},{"trials":997,"activeCount":59},[],{"trials":999,"activeCount":59},[],{"trials":1001,"activeCount":59},[],{"trials":1003,"activeCount":59},[],{"trials":1005,"activeCount":59},[1006],{"nctId":1007,"briefTitle":1008,"status":176,"phases":1009,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":589,"conditions":1013,"interventions":1016},"NCT04580355","Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome",[52],"2022-07","2022-10","2021-07",[1014,32,1015],"Microbial Colonization","Periodontal Inflammation",[994,1017,1018,1019],"Metronidazole 400mg","Amoxicillin Placebo","Metronidazole Placebo",{"trials":1021,"activeCount":59},[],{"intervention":1017,"totalTrials":75,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1038},{"trials":1025,"activeCount":59},[],{"trials":1027,"activeCount":59},[],{"trials":1029,"activeCount":59},[],{"trials":1031,"activeCount":59},[],{"trials":1033,"activeCount":59},[1034],{"nctId":1007,"briefTitle":1008,"status":176,"phases":1035,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":589,"conditions":1036,"interventions":1037},[52],[1014,32,1015],[994,1017,1018,1019],{"trials":1039,"activeCount":59},[],{"intervention":1018,"totalTrials":75,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1056},{"trials":1043,"activeCount":59},[],{"trials":1045,"activeCount":59},[],{"trials":1047,"activeCount":59},[],{"trials":1049,"activeCount":59},[],{"trials":1051,"activeCount":59},[1052],{"nctId":1007,"briefTitle":1008,"status":176,"phases":1053,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":589,"conditions":1054,"interventions":1055},[52],[1014,32,1015],[994,1017,1018,1019],{"trials":1057,"activeCount":59},[],{"intervention":1019,"totalTrials":75,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1074},{"trials":1061,"activeCount":59},[],{"trials":1063,"activeCount":59},[],{"trials":1065,"activeCount":59},[],{"trials":1067,"activeCount":59},[],{"trials":1069,"activeCount":59},[1070],{"nctId":1007,"briefTitle":1008,"status":176,"phases":1071,"primaryCompletion":1010,"completion":1011,"start":1012,"enrollment":589,"conditions":1072,"interventions":1073},[52],[1014,32,1015],[994,1017,1018,1019],{"trials":1075,"activeCount":59},[],{"intervention":1077,"totalTrials":11,"cells":1078},"Amlodipine",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1106,"NA":1108},{"trials":1080,"activeCount":59},[],{"trials":1082,"activeCount":59},[],{"trials":1084,"activeCount":59},[],{"trials":1086,"activeCount":59},[1087,1095],{"nctId":1088,"briefTitle":1089,"status":81,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":819,"enrollment":16,"conditions":1092,"interventions":1094},"NCT01125254","Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major",[50,51],"2011-07",[1093],"Thalassemia Major",[1077],{"nctId":1096,"briefTitle":1097,"status":81,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1105},"NCT01395199","Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major",[51],"2015-02","2012-08",62,[1103,1104],"Thalassemia","Iron Overload",[1077],{"trials":1107,"activeCount":59},[],{"trials":1109,"activeCount":59},[],{"intervention":1111,"totalTrials":11,"cells":1112},"Amitriptyline",{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1117,"PHASE3":1119,"PHASE4":1139,"NA":1141},{"trials":1114,"activeCount":59},[],{"trials":1116,"activeCount":59},[],{"trials":1118,"activeCount":59},[],{"trials":1120,"activeCount":59},[1121,1129],{"nctId":1122,"briefTitle":1123,"status":176,"phases":1124,"primaryCompletion":720,"completion":721,"start":722,"enrollment":1125,"conditions":1126,"interventions":1128},"NCT02871661","Physical Therapy as Adjuvant Treatment of Vulvodynia: a Randomized Controled Trial",[51],58,[1127],"Vulvodynia",[1111],{"nctId":1130,"briefTitle":1131,"status":81,"phases":1132,"primaryCompletion":1133,"completion":1133,"start":1134,"enrollment":1135,"conditions":1136,"interventions":1138},"NCT03587025","Preemptive Analgesia With Amitryptyline for Prevention of Pain in Women After Hysterectomy",[51],"2018-10-30","2015-06-01",150,[1137],"Pain, Postoperative",[1111],{"trials":1140,"activeCount":59},[],{"trials":1142,"activeCount":59},[],{"intervention":1144,"totalTrials":75,"cells":1145},"Liraglutide 3.0 mg",{"EARLY_PHASE1":1146,"PHASE1":1148,"PHASE2":1150,"PHASE3":1152,"PHASE4":1164,"NA":1166},{"trials":1147,"activeCount":59},[],{"trials":1149,"activeCount":59},[],{"trials":1151,"activeCount":59},[],{"trials":1153,"activeCount":59},[1154],{"nctId":1155,"briefTitle":1156,"status":176,"phases":1157,"primaryCompletion":1158,"completion":1159,"start":1160,"enrollment":304,"conditions":1161,"interventions":1163},"NCT02718950","Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans",[51],"2017-03","2017-04","2016-06",[18,1162],"Type 2 Diabetes Mellitus",[1144],{"trials":1165,"activeCount":59},[],{"trials":1167,"activeCount":59},[],{"intervention":1169,"totalTrials":75,"cells":1170},"Trimethoprim-Sulfamethoxazole",{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1188,"NA":1190},{"trials":1172,"activeCount":59},[],{"trials":1174,"activeCount":59},[],{"trials":1176,"activeCount":59},[],{"trials":1178,"activeCount":59},[1179],{"nctId":1180,"briefTitle":1181,"status":81,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":614,"enrollment":1184,"conditions":1185,"interventions":1187},"NCT01449877","Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis",[51],"2013-11",141,[1186],"Ocular Toxoplasmosis",[1169],{"trials":1189,"activeCount":59},[],{"trials":1191,"activeCount":59},[],{"intervention":1193,"totalTrials":75,"cells":1194},"dexamethasone 0.1%\u002Fpovidone-iodine 0.4%",{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1212,"NA":1214},{"trials":1196,"activeCount":59},[],{"trials":1198,"activeCount":59},[],{"trials":1200,"activeCount":59},[],{"trials":1202,"activeCount":59},[1203],{"nctId":1204,"briefTitle":1205,"status":81,"phases":1206,"primaryCompletion":417,"completion":1207,"start":542,"enrollment":375,"conditions":1208,"interventions":1210},"NCT01481519","A Trial of Topical Dexamethasone Versus Artificial Tears for Treatment of Viral Conjunctivitis",[51],"2013-02",[1209],"Viral Conjunctivitis",[1193,1211],"Artificial Tears",{"trials":1213,"activeCount":59},[],{"trials":1215,"activeCount":59},[],{"intervention":1211,"totalTrials":75,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1222,"PHASE3":1224,"PHASE4":1230,"NA":1232},{"trials":1219,"activeCount":59},[],{"trials":1221,"activeCount":59},[],{"trials":1223,"activeCount":59},[],{"trials":1225,"activeCount":59},[1226],{"nctId":1204,"briefTitle":1205,"status":81,"phases":1227,"primaryCompletion":417,"completion":1207,"start":542,"enrollment":375,"conditions":1228,"interventions":1229},[51],[1209],[1193,1211],{"trials":1231,"activeCount":59},[],{"trials":1233,"activeCount":59},[],{"intervention":1235,"totalTrials":75,"cells":1236},"Bacillus Calmette Guerin",{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1256,"NA":1258},{"trials":1238,"activeCount":59},[],{"trials":1240,"activeCount":59},[],{"trials":1242,"activeCount":59},[],{"trials":1244,"activeCount":59},[1245],{"nctId":1246,"briefTitle":1247,"status":81,"phases":1248,"primaryCompletion":1249,"completion":1250,"start":1251,"enrollment":589,"conditions":1252,"interventions":1255},"NCT04806178","Immunological Response of Bladder Cancer Patients Under BCG",[51],"2024-05-24","2024-08-18","2021-09-03",[1253,1254],"Bladder Cancer","Bacillus Calmette-Guerin",[1235],{"trials":1257,"activeCount":59},[],{"trials":1259,"activeCount":59},[],{"intervention":1261,"totalTrials":75,"cells":1262},"Moxifloxacin",{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1269,"PHASE4":1282,"NA":1284},{"trials":1264,"activeCount":59},[],{"trials":1266,"activeCount":59},[],{"trials":1268,"activeCount":59},[],{"trials":1270,"activeCount":59},[1271],{"nctId":1272,"briefTitle":1273,"status":1274,"phases":1275,"primaryCompletion":1276,"completion":1277,"start":85,"enrollment":1278,"conditions":1279,"interventions":1280},"NCT02770729","Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.","TERMINATED",[51],"2018-02","2018-05-07",3640,[34],[1261,1281],"No injection of moxifloxacin",{"trials":1283,"activeCount":59},[],{"trials":1285,"activeCount":59},[],{"intervention":1281,"totalTrials":75,"cells":1287},{"EARLY_PHASE1":1288,"PHASE1":1290,"PHASE2":1292,"PHASE3":1294,"PHASE4":1300,"NA":1302},{"trials":1289,"activeCount":59},[],{"trials":1291,"activeCount":59},[],{"trials":1293,"activeCount":59},[],{"trials":1295,"activeCount":59},[1296],{"nctId":1272,"briefTitle":1273,"status":1274,"phases":1297,"primaryCompletion":1276,"completion":1277,"start":85,"enrollment":1278,"conditions":1298,"interventions":1299},[51],[34],[1261,1281],{"trials":1301,"activeCount":59},[],{"trials":1303,"activeCount":59},[],{"intervention":1305,"totalTrials":11,"cells":1306},"Diacerein",{"EARLY_PHASE1":1307,"PHASE1":1309,"PHASE2":1311,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1308,"activeCount":59},[],{"trials":1310,"activeCount":59},[],{"trials":1312,"activeCount":59},[1313,1322],{"nctId":1314,"briefTitle":1315,"status":176,"phases":1316,"primaryCompletion":1317,"completion":1318,"start":1319,"enrollment":136,"conditions":1320,"interventions":1321},"NCT05226754","Study Design of the Diacerein in Patients With Covid-19",[50],"2023-06-30","2023-07-08","2022-04-01",[208],[1305],{"nctId":1323,"briefTitle":1324,"status":176,"phases":1325,"primaryCompletion":491,"start":613,"enrollment":259,"conditions":1326,"interventions":1328},"NCT02177643","Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin",[50],[1327,15,23],"Diabetes-Related Complications",[1305],{"trials":1330,"activeCount":59},[],{"trials":1332,"activeCount":59},[],{"trials":1334,"activeCount":59},[],{"intervention":1336,"totalTrials":75,"cells":1337},"Autologous dendritic cells electroporated with WT1 mRNA",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1353,"PHASE4":1355,"NA":1357},{"trials":1339,"activeCount":59},[],{"trials":1341,"activeCount":59},[],{"trials":1343,"activeCount":59},[1344],{"nctId":1345,"briefTitle":1346,"status":176,"phases":1347,"primaryCompletion":1348,"completion":1012,"start":491,"enrollment":847,"conditions":1349,"interventions":1352},"NCT03083054","Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia",[49,50],"2020-07-12",[1350,1351],"Myelodysplastic Syndromes","Acute Myeloid Leukemia",[1336],{"trials":1354,"activeCount":59},[],{"trials":1356,"activeCount":59},[],{"trials":1358,"activeCount":59},[],{"intervention":1360,"totalTrials":75,"cells":1361},"Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1380,"PHASE4":1382,"NA":1384},{"trials":1363,"activeCount":59},[],{"trials":1365,"activeCount":59},[],{"trials":1367,"activeCount":59},[1368],{"nctId":1369,"briefTitle":1370,"status":176,"phases":1371,"primaryCompletion":1372,"completion":1373,"start":1374,"enrollment":375,"conditions":1375,"interventions":1378},"NCT05162625","Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial",[50],"2022-12-10","2023-12-10","2021-12-10",[34,1376,1261,1377],"Open Globe Injury","Post-Traumatic Endophthalmitis",[1360,1379],"Ciprofloxacin 400 MG\u002F200 ML Intravenous Solution [CIPRO IV]",{"trials":1381,"activeCount":59},[],{"trials":1383,"activeCount":59},[],{"trials":1385,"activeCount":59},[],{"intervention":1379,"totalTrials":75,"cells":1387},{"EARLY_PHASE1":1388,"PHASE1":1390,"PHASE2":1392,"PHASE3":1398,"PHASE4":1400,"NA":1402},{"trials":1389,"activeCount":59},[],{"trials":1391,"activeCount":59},[],{"trials":1393,"activeCount":59},[1394],{"nctId":1369,"briefTitle":1370,"status":176,"phases":1395,"primaryCompletion":1372,"completion":1373,"start":1374,"enrollment":375,"conditions":1396,"interventions":1397},[50],[34,1376,1261,1377],[1360,1379],{"trials":1399,"activeCount":59},[],{"trials":1401,"activeCount":59},[],{"trials":1403,"activeCount":59},[],{"intervention":1405,"totalTrials":75,"cells":1406},"Metformin XR",{"EARLY_PHASE1":1407,"PHASE1":1409,"PHASE2":1411,"PHASE3":1423,"PHASE4":1425,"NA":1427},{"trials":1408,"activeCount":59},[],{"trials":1410,"activeCount":59},[],{"trials":1412,"activeCount":59},[1413],{"nctId":1414,"briefTitle":1415,"status":176,"phases":1416,"primaryCompletion":1276,"completion":1417,"start":85,"enrollment":1418,"conditions":1419,"interventions":1421},"NCT02967276","Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma",[50],"2020-02",28,[1420],"Multiple Myeloma",[1405,1422],"Dexamethasone",{"trials":1424,"activeCount":59},[],{"trials":1426,"activeCount":59},[],{"trials":1428,"activeCount":59},[],{"intervention":1422,"totalTrials":75,"cells":1430},{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1441,"PHASE4":1443,"NA":1445},{"trials":1432,"activeCount":59},[],{"trials":1434,"activeCount":59},[],{"trials":1436,"activeCount":59},[1437],{"nctId":1414,"briefTitle":1415,"status":176,"phases":1438,"primaryCompletion":1276,"completion":1417,"start":85,"enrollment":1418,"conditions":1439,"interventions":1440},[50],[1420],[1405,1422],{"trials":1442,"activeCount":59},[],{"trials":1444,"activeCount":59},[],{"trials":1446,"activeCount":59},[],{"intervention":1448,"totalTrials":75,"cells":1449},"Metronidazole",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1454,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1451,"activeCount":59},[],{"trials":1453,"activeCount":59},[],{"trials":1455,"activeCount":59},[1456],{"nctId":1457,"briefTitle":1458,"status":81,"phases":1459,"primaryCompletion":588,"completion":542,"start":1460,"enrollment":589,"conditions":1461,"interventions":1463},"NCT01938183","Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis",[50],"2006-11",[1462],"Chronic Periodontitis",[1448,1464],"Metronidazole benzoate gel",{"trials":1466,"activeCount":59},[],{"trials":1468,"activeCount":59},[],{"trials":1470,"activeCount":59},[],{"intervention":1464,"totalTrials":75,"cells":1472},{"EARLY_PHASE1":1473,"PHASE1":1475,"PHASE2":1477,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1474,"activeCount":59},[],{"trials":1476,"activeCount":59},[],{"trials":1478,"activeCount":59},[1479],{"nctId":1457,"briefTitle":1458,"status":81,"phases":1480,"primaryCompletion":588,"completion":542,"start":1460,"enrollment":589,"conditions":1481,"interventions":1482},[50],[1462],[1448,1464],{"trials":1484,"activeCount":59},[],{"trials":1486,"activeCount":59},[],{"trials":1488,"activeCount":59},[],{"intervention":1490,"totalTrials":75,"cells":1491},"Pioglitazone 30 Mg Oral",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1508,"PHASE4":1510,"NA":1512},{"trials":1493,"activeCount":59},[],{"trials":1495,"activeCount":59},[],{"trials":1497,"activeCount":59},[1498],{"nctId":1499,"briefTitle":1500,"status":81,"phases":1501,"primaryCompletion":1502,"completion":1502,"start":1503,"enrollment":1504,"conditions":1505,"interventions":1507},"NCT02852486","Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response",[50],"2024-02-07","2016-06-22",31,[1506],"Leukemia, Chronic Myeloid",[1490],{"trials":1509,"activeCount":59},[],{"trials":1511,"activeCount":59},[],{"trials":1513,"activeCount":59},[],{"intervention":1515,"totalTrials":75,"cells":1516},"Green tea extract",{"EARLY_PHASE1":1517,"PHASE1":1519,"PHASE2":1521,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1518,"activeCount":59},[],{"trials":1520,"activeCount":59},[],{"trials":1522,"activeCount":59},[1523],{"nctId":1524,"briefTitle":1525,"status":81,"phases":1526,"primaryCompletion":444,"completion":444,"start":1183,"enrollment":896,"conditions":1527,"interventions":1529},"NCT01923597","Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.",[50],[1528,26],"Diabetic Nephropathy",[1515],{"trials":1531,"activeCount":59},[],{"trials":1533,"activeCount":59},[],{"trials":1535,"activeCount":59},[],{"intervention":1537,"totalTrials":75,"cells":1538},"Platelets Rich Plasma",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1540,"activeCount":59},[],{"trials":1542,"activeCount":59},[],{"trials":1544,"activeCount":59},[1545],{"nctId":1546,"briefTitle":1547,"status":176,"phases":1548,"primaryCompletion":1549,"start":1183,"enrollment":1550,"conditions":1551,"interventions":1553},"NCT02923310","Evaluation of Two Types of PRP in Knee Osteoarthritis",[49,50],"2016-09",120,[1552],"Osteoarthrosis",[1537,1554,1555],"Leucocyte - Platelets Rich Plasma","Hialuronic Acid",{"trials":1557,"activeCount":59},[],{"trials":1559,"activeCount":59},[],{"trials":1561,"activeCount":59},[],{"intervention":1554,"totalTrials":75,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1565,"activeCount":59},[],{"trials":1567,"activeCount":59},[],{"trials":1569,"activeCount":59},[1570],{"nctId":1546,"briefTitle":1547,"status":176,"phases":1571,"primaryCompletion":1549,"start":1183,"enrollment":1550,"conditions":1572,"interventions":1573},[49,50],[1552],[1537,1554,1555],{"trials":1575,"activeCount":59},[],{"trials":1577,"activeCount":59},[],{"trials":1579,"activeCount":59},[],{"intervention":1555,"totalTrials":75,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1592,"PHASE4":1594,"NA":1596},{"trials":1583,"activeCount":59},[],{"trials":1585,"activeCount":59},[],{"trials":1587,"activeCount":59},[1588],{"nctId":1546,"briefTitle":1547,"status":176,"phases":1589,"primaryCompletion":1549,"start":1183,"enrollment":1550,"conditions":1590,"interventions":1591},[49,50],[1552],[1537,1554,1555],{"trials":1593,"activeCount":59},[],{"trials":1595,"activeCount":59},[],{"trials":1597,"activeCount":59},[],{"intervention":1599,"totalTrials":75,"cells":1600},"Simvastatin 40mg",{"EARLY_PHASE1":1601,"PHASE1":1603,"PHASE2":1605,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1602,"activeCount":59},[],{"trials":1604,"activeCount":59},[],{"trials":1606,"activeCount":59},[1607],{"nctId":1608,"briefTitle":1609,"status":176,"phases":1610,"primaryCompletion":1611,"completion":1012,"start":1612,"enrollment":1418,"conditions":1613,"interventions":1616},"NCT03599609","Central Nervous System Vascular Changes in Adult Sickle Cell Disease and the Effect of Treatment With Simvastatin",[49,50],"2020-01-14","2018-03-05",[1614,1615],"Sickle Cell Disease","Stroke",[1599],{"trials":1618,"activeCount":59},[],{"trials":1620,"activeCount":59},[],{"trials":1622,"activeCount":59},[],{"intervention":1624,"totalTrials":75,"cells":1625},"Doxycycline",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1627,"activeCount":59},[],{"trials":1629,"activeCount":59},[],{"trials":1631,"activeCount":59},[1632],{"nctId":1633,"briefTitle":1634,"status":81,"phases":1635,"primaryCompletion":1636,"completion":1158,"start":587,"enrollment":136,"conditions":1637,"interventions":1638},"NCT02726646","Evaluation of Local Doxycycline in Smokers With Chronic Periodontitis",[50],"2016-11",[1462],[1624],{"trials":1640,"activeCount":59},[],{"trials":1642,"activeCount":59},[],{"trials":1644,"activeCount":59},[],{"intervention":1646,"totalTrials":75,"cells":1647},"Capecitabine",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1649,"activeCount":59},[],{"trials":1651,"activeCount":59},[],{"trials":1653,"activeCount":59},[1654],{"nctId":1655,"briefTitle":1656,"status":1274,"phases":1657,"primaryCompletion":769,"completion":769,"start":1658,"enrollment":35,"conditions":1659,"interventions":1663},"NCT02473094","Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer",[50],"2015-07",[1660,1661,1662],"Rectal Neoplasms","Adenocarcinoma","Carcinoma",[1646,1664],"Metformin",{"trials":1666,"activeCount":59},[],{"trials":1668,"activeCount":59},[],{"trials":1670,"activeCount":59},[],{"intervention":1664,"totalTrials":75,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":59},[],{"trials":1676,"activeCount":59},[],{"trials":1678,"activeCount":59},[1679],{"nctId":1655,"briefTitle":1656,"status":1274,"phases":1680,"primaryCompletion":769,"completion":769,"start":1658,"enrollment":35,"conditions":1681,"interventions":1682},[50],[1660,1661,1662],[1646,1664],{"trials":1684,"activeCount":59},[],{"trials":1686,"activeCount":59},[],{"trials":1688,"activeCount":59},[],{"intervention":1690,"totalTrials":75,"cells":1691},"topic cream insulin",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1693,"activeCount":59},[],{"trials":1695,"activeCount":59},[],{"trials":1697,"activeCount":59},[1698],{"nctId":1699,"briefTitle":1700,"status":81,"phases":1701,"primaryCompletion":1702,"completion":1703,"start":1704,"enrollment":1705,"conditions":1706,"interventions":1709},"NCT01295177","Topic Insulin Accelerates Wound Healing in Diabetes",[49,50],"2007-08","2007-09","2004-01",22,[1707,1708],"Diabetes Mellitus","Wounds",[1690],{"trials":1711,"activeCount":59},[],{"trials":1713,"activeCount":59},[],{"trials":1715,"activeCount":59},[],{"intervention":1717,"totalTrials":11,"cells":1718},"Topical anesthetic",{"EARLY_PHASE1":1719,"PHASE1":1721,"PHASE2":1746,"PHASE3":1748,"PHASE4":1750,"NA":1752},{"trials":1720,"activeCount":59},[],{"trials":1722,"activeCount":59},[1723,1735],{"nctId":1724,"briefTitle":1725,"status":81,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":136,"conditions":1730,"interventions":1734},"NCT05912335","Clinical Efficiency of Xanthan Hydrogels Containing Local Anesthetics Encapsulated in Nanostructured Lipid Carries",[49],"2022-02-20","2022-05-03","2021-06-02",[1731,1732,1733],"Dental Trauma","Local Anesthesia","Oral Cavity Disease",[1717],{"nctId":1736,"briefTitle":1737,"status":81,"phases":1738,"primaryCompletion":1739,"completion":1740,"start":1741,"enrollment":589,"conditions":1742,"interventions":1743},"NCT05267938","Microneedle Pretreatment as a Strategy to Improve the Effectiveness of Topical Anesthetics Formulations",[49],"2019-10-30","2020-01-30","2019-08-01",[1733],[1744,1745],"Topical Anesthetic","Local anesthetic",{"trials":1747,"activeCount":59},[],{"trials":1749,"activeCount":59},[],{"trials":1751,"activeCount":59},[],{"trials":1753,"activeCount":59},[],{"intervention":1755,"totalTrials":11,"cells":1756},"Ropivacaine",{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1781,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1758,"activeCount":59},[],{"trials":1760,"activeCount":59},[1761,1772],{"nctId":1762,"briefTitle":1763,"status":81,"phases":1764,"primaryCompletion":1765,"completion":1766,"start":329,"enrollment":71,"conditions":1767,"interventions":1771},"NCT01054547","Topical Formulations of Liposomal Local Anesthetics",[49],"2006-12","2007-04",[1768,1769,1770],"Administration, Topical Drug","Administration, Topical","Anesthetic Drugs",[1755,1755],{"nctId":1773,"briefTitle":1774,"status":81,"phases":1775,"primaryCompletion":1776,"completion":327,"start":1777,"enrollment":136,"conditions":1778,"interventions":1780},"NCT01307969","Formulations of Liposomal Local Anesthetics",[49],"2007-05","2007-02",[1779],"Underdosing of Local Anesthetics, Initial Encounter",[1755],{"trials":1782,"activeCount":59},[],{"trials":1784,"activeCount":59},[],{"trials":1786,"activeCount":59},[],{"trials":1788,"activeCount":59},[],{"intervention":1790,"totalTrials":11,"cells":1791},"Toothpaste",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1813,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1793,"activeCount":59},[],{"trials":1795,"activeCount":59},[1796,1804],{"nctId":1797,"briefTitle":1798,"status":81,"phases":1799,"primaryCompletion":1800,"completion":419,"start":134,"enrollment":1801,"conditions":1802,"interventions":1803},"NCT01589458","Fluoride Availability in Saliva After Use of Sodium Fluoride or Monofluorophosphate Toothpastes",[49],"2012-02",12,[20],[1790],{"nctId":1805,"briefTitle":1806,"status":81,"phases":1807,"primaryCompletion":417,"completion":1808,"start":894,"enrollment":1809,"conditions":1810,"interventions":1812},"NCT01589991","Anticaries Potential and Fluorosis Risk From Different Fluoride Toothpastes",[49],"2013-07",24,[20,1811],"Dental Fluorosis",[1790],{"trials":1814,"activeCount":59},[],{"trials":1816,"activeCount":59},[],{"trials":1818,"activeCount":59},[],{"trials":1820,"activeCount":59},[],{"intervention":1822,"totalTrials":75,"cells":1823},"Maltodextrin",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1825,"activeCount":59},[],{"trials":1827,"activeCount":59},[1828],{"nctId":1829,"briefTitle":1830,"status":81,"phases":1831,"primaryCompletion":419,"completion":1808,"start":1832,"enrollment":304,"conditions":1833,"interventions":1835},"NCT02183766","GOS Prebiotic Effect in Children Constipation",[49],"2010-04",[1834],"Constipation",[1822],{"trials":1837,"activeCount":59},[],{"trials":1839,"activeCount":59},[],{"trials":1841,"activeCount":59},[],{"trials":1843,"activeCount":59},[],{"intervention":1745,"totalTrials":75,"cells":1845},{"EARLY_PHASE1":1846,"PHASE1":1848,"PHASE2":1854,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1847,"activeCount":59},[],{"trials":1849,"activeCount":59},[1850],{"nctId":1736,"briefTitle":1737,"status":81,"phases":1851,"primaryCompletion":1739,"completion":1740,"start":1741,"enrollment":589,"conditions":1852,"interventions":1853},[49],[1733],[1744,1745],{"trials":1855,"activeCount":59},[],{"trials":1857,"activeCount":59},[],{"trials":1859,"activeCount":59},[],{"trials":1861,"activeCount":59},[],{"intervention":1863,"totalTrials":75,"cells":1864},"Purified water",{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1879,"PHASE3":1881,"PHASE4":1883,"NA":1885},{"trials":1866,"activeCount":59},[],{"trials":1868,"activeCount":59},[1869],{"nctId":1870,"briefTitle":1871,"status":81,"phases":1872,"primaryCompletion":134,"completion":542,"start":894,"enrollment":304,"conditions":1873,"interventions":1874},"NCT01571050","Systemic Fluoride Bioavailability From Toothpastes Containing Calcium Carbonate or Silica as Abrasives",[49],[1811],[1863,1875,1876,1877,1878],"Fresh MFP\u002FCaCO3 toothpaste","Fresh NaF\u002FSiO2 toothpaste","Aged NaF\u002FSiO2 toothpaste","Aged MFP\u002FCaCO3 toothpaste",{"trials":1880,"activeCount":59},[],{"trials":1882,"activeCount":59},[],{"trials":1884,"activeCount":59},[],{"trials":1886,"activeCount":59},[],{"intervention":1875,"totalTrials":75,"cells":1888},{"EARLY_PHASE1":1889,"PHASE1":1891,"PHASE2":1897,"PHASE3":1899,"PHASE4":1901,"NA":1903},{"trials":1890,"activeCount":59},[],{"trials":1892,"activeCount":59},[1893],{"nctId":1870,"briefTitle":1871,"status":81,"phases":1894,"primaryCompletion":134,"completion":542,"start":894,"enrollment":304,"conditions":1895,"interventions":1896},[49],[1811],[1863,1875,1876,1877,1878],{"trials":1898,"activeCount":59},[],{"trials":1900,"activeCount":59},[],{"trials":1902,"activeCount":59},[],{"trials":1904,"activeCount":59},[],{"intervention":1876,"totalTrials":75,"cells":1906},{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1915,"PHASE3":1917,"PHASE4":1919,"NA":1921},{"trials":1908,"activeCount":59},[],{"trials":1910,"activeCount":59},[1911],{"nctId":1870,"briefTitle":1871,"status":81,"phases":1912,"primaryCompletion":134,"completion":542,"start":894,"enrollment":304,"conditions":1913,"interventions":1914},[49],[1811],[1863,1875,1876,1877,1878],{"trials":1916,"activeCount":59},[],{"trials":1918,"activeCount":59},[],{"trials":1920,"activeCount":59},[],{"trials":1922,"activeCount":59},[],{"intervention":1877,"totalTrials":75,"cells":1924},{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1939},{"trials":1926,"activeCount":59},[],{"trials":1928,"activeCount":59},[1929],{"nctId":1870,"briefTitle":1871,"status":81,"phases":1930,"primaryCompletion":134,"completion":542,"start":894,"enrollment":304,"conditions":1931,"interventions":1932},[49],[1811],[1863,1875,1876,1877,1878],{"trials":1934,"activeCount":59},[],{"trials":1936,"activeCount":59},[],{"trials":1938,"activeCount":59},[],{"trials":1940,"activeCount":59},[],{"intervention":1878,"totalTrials":75,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1944,"activeCount":59},[],{"trials":1946,"activeCount":59},[1947],{"nctId":1870,"briefTitle":1871,"status":81,"phases":1948,"primaryCompletion":134,"completion":542,"start":894,"enrollment":304,"conditions":1949,"interventions":1950},[49],[1811],[1863,1875,1876,1877,1878],{"trials":1952,"activeCount":59},[],{"trials":1954,"activeCount":59},[],{"trials":1956,"activeCount":59},[],{"trials":1958,"activeCount":59},[],{"intervention":1960,"totalTrials":75,"cells":1961},"Prilocaine",{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1976,"PHASE3":1978,"PHASE4":1980,"NA":1982},{"trials":1963,"activeCount":59},[],{"trials":1965,"activeCount":59},[1966],{"nctId":1967,"briefTitle":1968,"status":81,"phases":1969,"primaryCompletion":1970,"completion":1971,"start":1972,"enrollment":518,"conditions":1973,"interventions":1975},"NCT01073371","Anesthetic Efficacy of Liposomal Prilocaine in Maxillary Infiltration Anesthesia",[49],"2009-08","2009-11","2008-07",[1974],"Dental Anesthesia Efficacy",[1960],{"trials":1977,"activeCount":59},[],{"trials":1979,"activeCount":59},[],{"trials":1981,"activeCount":59},[],{"trials":1983,"activeCount":59},[],{"intervention":1985,"totalTrials":75,"cells":1986},"mepivacaine",{"EARLY_PHASE1":1987,"PHASE1":1989,"PHASE2":1999,"PHASE3":2001,"PHASE4":2003,"NA":2005},{"trials":1988,"activeCount":59},[],{"trials":1990,"activeCount":59},[1991],{"nctId":1992,"briefTitle":1993,"status":81,"phases":1994,"completion":1995,"start":1776,"enrollment":589,"conditions":1996,"interventions":1998},"NCT01032798","Local Anesthetics New Formulations: From Development to Clinical Tests",[49],"2008-05",[1997],"Local Anesthetic Effectiveness",[1985],{"trials":2000,"activeCount":59},[],{"trials":2002,"activeCount":59},[],{"trials":2004,"activeCount":59},[],{"trials":2006,"activeCount":59},[],{"intervention":2008,"totalTrials":75,"cells":2009},"Lidocaine",{"EARLY_PHASE1":2010,"PHASE1":2012,"PHASE2":2024,"PHASE3":2026,"PHASE4":2028,"NA":2030},{"trials":2011,"activeCount":59},[],{"trials":2013,"activeCount":59},[2014],{"nctId":2015,"briefTitle":2016,"status":81,"phases":2017,"primaryCompletion":2018,"completion":2019,"start":2020,"enrollment":136,"conditions":2021,"interventions":2023},"NCT01425840","Liposomal Lidocaine Gel for Oral Topical Anesthesia",[49],"2008-11","2009-03","2008-03",[2022],"Anesthesia",[2008],{"trials":2025,"activeCount":59},[],{"trials":2027,"activeCount":59},[],{"trials":2029,"activeCount":59},[],{"trials":2031,"activeCount":59},[],{"intervention":2033,"totalTrials":75,"cells":2034},"5% sodium fluoride varnish",{"EARLY_PHASE1":2035,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2052,"NA":2054},{"trials":2036,"activeCount":59},[2037],{"nctId":2038,"briefTitle":2039,"status":81,"phases":2040,"primaryCompletion":2041,"completion":466,"start":2042,"enrollment":1101,"conditions":2043,"interventions":2044},"NCT02486458","Long-term Release of Fluoride Formed on Enamel by Fluoride Gel or Varnish to Biofilm Fluid",[48],"2015-12","2015-04",[20],[2033,2045],"1.23% sodium fluoride acidic gel",{"trials":2047,"activeCount":59},[],{"trials":2049,"activeCount":59},[],{"trials":2051,"activeCount":59},[],{"trials":2053,"activeCount":59},[],{"trials":2055,"activeCount":59},[],{"intervention":2045,"totalTrials":75,"cells":2057},{"EARLY_PHASE1":2058,"PHASE1":2064,"PHASE2":2066,"PHASE3":2068,"PHASE4":2070,"NA":2072},{"trials":2059,"activeCount":59},[2060],{"nctId":2038,"briefTitle":2039,"status":81,"phases":2061,"primaryCompletion":2041,"completion":466,"start":2042,"enrollment":1101,"conditions":2062,"interventions":2063},[48],[20],[2033,2045],{"trials":2065,"activeCount":59},[],{"trials":2067,"activeCount":59},[],{"trials":2069,"activeCount":59},[],{"trials":2071,"activeCount":59},[],{"trials":2073,"activeCount":59},[],{"intervention":2075,"totalTrials":11,"cells":2076},"Orlistat",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2078,"activeCount":59},[],{"trials":2080,"activeCount":59},[],{"trials":2082,"activeCount":59},[],{"trials":2084,"activeCount":59},[],{"trials":2086,"activeCount":59},[],{"trials":2088,"activeCount":59},[2089,2098],{"nctId":2090,"briefTitle":2091,"status":81,"phases":2092,"primaryCompletion":588,"completion":2093,"start":2094,"enrollment":9,"conditions":2095,"interventions":2097},"NCT01414465","Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females",[53],"2011-06","2009-10",[2096],"Overweight",[2075],{"nctId":2099,"briefTitle":2100,"status":81,"phases":2101,"primaryCompletion":588,"completion":1832,"start":2094,"enrollment":304,"conditions":2102,"interventions":2103},"NCT01170806","Study of Fat Malabsorption by Lipiblock Versus Xenical",[53],[18],[2075],{"intervention":2105,"totalTrials":75,"cells":2106},"Doxorubicin",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2113,"PHASE4":2115,"NA":2117},{"trials":2108,"activeCount":59},[],{"trials":2110,"activeCount":59},[],{"trials":2112,"activeCount":59},[],{"trials":2114,"activeCount":59},[],{"trials":2116,"activeCount":59},[],{"trials":2118,"activeCount":59},[2119],{"nctId":2120,"briefTitle":2121,"status":81,"phases":2122,"primaryCompletion":2123,"completion":722,"start":612,"enrollment":2124,"conditions":2125,"interventions":2128},"NCT03000036","Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients",[53],"2015-01",27,[2126,2127],"Breast Cancer Female","Doxorubicin Induced Cardiomyopathy",[2105,2129],"Gadoterate Meglumine",{"intervention":2129,"totalTrials":75,"cells":2131},{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2138,"PHASE4":2140,"NA":2142},{"trials":2133,"activeCount":59},[],{"trials":2135,"activeCount":59},[],{"trials":2137,"activeCount":59},[],{"trials":2139,"activeCount":59},[],{"trials":2141,"activeCount":59},[],{"trials":2143,"activeCount":59},[2144],{"nctId":2120,"briefTitle":2121,"status":81,"phases":2145,"primaryCompletion":2123,"completion":722,"start":612,"enrollment":2124,"conditions":2146,"interventions":2147},[53],[2126,2127],[2105,2129],{"intervention":2149,"totalTrials":75,"cells":2150},"cefazolin",{"EARLY_PHASE1":2151,"PHASE1":2153,"PHASE2":2155,"PHASE3":2157,"PHASE4":2159,"NA":2161},{"trials":2152,"activeCount":59},[],{"trials":2154,"activeCount":59},[],{"trials":2156,"activeCount":59},[],{"trials":2158,"activeCount":59},[],{"trials":2160,"activeCount":59},[],{"trials":2162,"activeCount":59},[2163],{"nctId":2164,"briefTitle":2165,"status":176,"phases":2166,"primaryCompletion":820,"completion":820,"start":2167,"enrollment":2168,"conditions":2169,"interventions":2171},"NCT00787553","Tinidazole Versus Cefazolin Antibiotic Prophylaxis of Vaginal and Abdominal Hysterectomy",[53],"2006-07",75,[2170],"Hysterectomy",[2149,2172,2173],"tinidazole","cefazolin plus tinidazole",{"intervention":2172,"totalTrials":75,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2177,"activeCount":59},[],{"trials":2179,"activeCount":59},[],{"trials":2181,"activeCount":59},[],{"trials":2183,"activeCount":59},[],{"trials":2185,"activeCount":59},[],{"trials":2187,"activeCount":59},[2188],{"nctId":2164,"briefTitle":2165,"status":176,"phases":2189,"primaryCompletion":820,"completion":820,"start":2167,"enrollment":2168,"conditions":2190,"interventions":2191},[53],[2170],[2149,2172,2173],{"intervention":2173,"totalTrials":75,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2202,"NA":2204},{"trials":2195,"activeCount":59},[],{"trials":2197,"activeCount":59},[],{"trials":2199,"activeCount":59},[],{"trials":2201,"activeCount":59},[],{"trials":2203,"activeCount":59},[],{"trials":2205,"activeCount":59},[2206],{"nctId":2164,"briefTitle":2165,"status":176,"phases":2207,"primaryCompletion":820,"completion":820,"start":2167,"enrollment":2168,"conditions":2208,"interventions":2209},[53],[2170],[2149,2172,2173],{"intervention":2211,"totalTrials":75,"cells":2212},"sildenafil",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2219,"PHASE4":2221,"NA":2223},{"trials":2214,"activeCount":59},[],{"trials":2216,"activeCount":59},[],{"trials":2218,"activeCount":59},[],{"trials":2220,"activeCount":59},[],{"trials":2222,"activeCount":59},[],{"trials":2224,"activeCount":59},[2225],{"nctId":2226,"briefTitle":2227,"status":81,"phases":2228,"primaryCompletion":612,"completion":2229,"start":2230,"enrollment":1550,"conditions":2231,"interventions":2232},"NCT01392638","Effects of Sildenafil in Resistant Hypertensives and Genetic Polymorphism",[53],"2012-09","2010-07",[26],[2211],{"intervention":2234,"totalTrials":75,"cells":2235},"Tadalafil",{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2242,"PHASE4":2244,"NA":2246},{"trials":2237,"activeCount":59},[],{"trials":2239,"activeCount":59},[],{"trials":2241,"activeCount":59},[],{"trials":2243,"activeCount":59},[],{"trials":2245,"activeCount":59},[],{"trials":2247,"activeCount":59},[2248],{"nctId":2249,"briefTitle":2250,"status":81,"phases":2251,"primaryCompletion":2252,"completion":1100,"start":2253,"enrollment":304,"conditions":2254,"interventions":2255},"NCT01743911","Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients",[53],"2012-04","2010-09",[26],[2234],{"intervention":2257,"totalTrials":75,"cells":2258},"full mouth ultrassonic debridement associated to Amoxicilin 500 + Metronidazole 400 mg",{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2267,"NA":2269},{"trials":2260,"activeCount":59},[],{"trials":2262,"activeCount":59},[],{"trials":2264,"activeCount":59},[],{"trials":2266,"activeCount":59},[],{"trials":2268,"activeCount":59},[],{"trials":2270,"activeCount":59},[2271],{"nctId":2272,"briefTitle":2273,"status":176,"phases":2274,"primaryCompletion":2275,"completion":2275,"start":2276,"enrollment":589,"conditions":2277,"interventions":2278},"NCT04051255","Influence of Smoking on Clinical, Microbiological and Immunologic Parameters in Patients With Aggressive Periodontitis.",[53],"2020-03-01","2017-03-01",[32,772],[2257]]